Dear Investors,

Bladder cancer has remained one of the most expensive and persistent cancers on Earth—with limited treatment options and staggering recurrence rates.That ends now.

We’re excited to invite you to a private, invitation-only investor reception on Wednesday, August 13 at 5:30PM PT in New York City, NY, featuring Combat Medical, a MedTech company revolutionizing the way we treat some of the world’s most expensive and recurring cancers.

Combat Medical is the first and only company to deliver effective, affordable, and tolerable treatment for the world’s most expensive cancers. The Company has developed two CE-marked drug delivery systems that use localized heat-enhanced chemotherapy (HIVEC®) to dramatically improve outcomes in bladder and peritoneal cancer treatment—areas with few options and high recurrence.

This breakthrough platform delivers chemotherapy directly to the tumor site using precision heat, improving drug absorption, immune response (including activation of natural killer cells), and patient comfort, while reducing side effects and impairing tumor growth. Already used in 35+ countries with 100,000+ treatments delivered, Combat is now entering the U.S. market.

The Investment Opportunity:

• Now raising: $5 million Series A

• $2.7 million already committed

• Funds support: $7M pivotal FDA trial and U.S. market entry

• Interim trial results expected end of 2026; final FDA approval targeted for 2029

• Valuation inflection point anticipated following interim data

• Comparable U.S. drug companies with weaker data have gone public at ~$1.8B valuations

• Backed by $20M to date, including $4M in non-dilutive government grants

• Self-funded operations and profitable international sales

Why Combat Medical?

Validated Technology with Global Traction

Combat’s HIVEC® platform has generated strong international commercial momentum, with $4.3M in 2024 revenue and positive EBITDA. The company’s “razorblade” model provides capital equipment free and monetizes single-use kits—90% of revenue—per treatment.

Massive Market with Urgent Need

Bladder cancer is the most expensive cancer to treat per patient. In the U.S. alone, 60,000 new NMIBC cases occur each year, with recurrence rates over 70%. Combat targets a $600M U.S. obtainable market within an $8B global TAM.

First-Mover Advantage with FDA Momentum

Combat has launched its FDA-reviewed HIVEC® Heat bladder trial, with interim data expected by late 2026. The company is uniquely positioned to lead the U.S. market for BCG-unresponsive NMIBC—a patient segment with few effective options.

Proven Team and Strategic Vision

Founded by Edward Bruce-White and Alberto Martinez, Combat combines medical expertise, commercial execution, and a clear path to exit—offering investors both meaningful impact and a de-risked path to value creation.

Why You Should Attend

This is a rare opportunity to back a clinically proven, revenue-generating MedTech platform poised for U.S. expansion, FDA approval, and significant investor upside. Join a select group of investors for a private, inside look at Combat Medical’s next chapter.

PLEASE NOTE: The minimum investment amount is $100,000

Event Details – Limited to Select Investors

📍 Location: The Capital Grille

120 W 5st St,

New York, NY 10020

📅 Date: Wednesday, August 13, 2025

🕔 Time: 5:30 PM ET

⚠️ Exclusive Invite-Only Event – Seats Are Extremely Limited ⚠️

Light fare and refreshments will be served.

This invitation is extended only to accredited investors, family offices, and investment advisors. RSVP now to secure your place.

For details, or to request the executive summary or investment deck, please contact Skylar Rallison at srallison@opus8.com.

Secure your spot today. Spaces are limited and subject to review. We look forward to hosting you and sharing how Combat Medical is changing the future of cancer treatment—one patient, one system at a time.

Best regards,

Tien Wong

CEO

Opus8, Inc.